Energy balance
Tirzepatide, a dual GLP-1/GIP agonist, may enhance metabolic efficiency and endurance performance by optimizing fat oxidation, delaying glycogen depletion, and improving mitochondrial function.
If you are an endurance athlete using tirzepatide, you may experience improved metabolic efficiency. The drug can help spare glycogen stores and enhance mitochondrial function, potentially supporting longer exercise durations. However, monitor for signs of hypoglycemia during high-intensity training and ensure adequate carbohydrate intake to counteract potential energy deficits.
Tirzepatide seems particularly intriguing in this regard... It has a beneficial effect on aerobic endurance by delaying the depletion of glycogen stores... The fundamental biological mechanisms that are at play involve a significant enhancement of mitochondrial function along with an increase in biogenesis...
Why this rating
Based on mechanistic descriptions and preliminary observations in the review, not large-scale performance trials.
Source
NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH
Bartosz Skorupski et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.3(47).2025.3678
More from this paper
- GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.Good
- Off-label use of GLP-1 agonists by healthy athletes for aesthetic or performance purposes raises ethical, legal, and safety concerns, including potential classification as doping and inequality in sports access.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →